• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Valneva (Group)

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various clinical-stage vaccines in development including unique vaccines against Lyme disease and chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees. *

 

	Start	2013-05-28 merged
	Predecessor	Vivalis (Group)
	Industry	avian (bird) production technology (transgenic)
	Industry 2	vaccine
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Grimaud, Franck (Vivalis 200702 CEO)
	Region	Lyon
	Country	France
	Street	6 rue Alain Bombard Campus Bio-Quest
	City	44800 Saint-Herblain
		Address record changed: 2020-12-02
Basic data	Employees	E: 501 to 1,000 (2021-09-30)
	Currency	EUR
	Annual sales	110,321,000 (revenues, total, consolidated (2020) 2020-12-31)
	Profit	-64,393,000 (2020-12-31)
	Cash	329,766,000 (2021-06-30)
		* Document for �About Section�: Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain.
		Record changed: 2021-10-30

Advertisement

More documents for Valneva (Group)

• [1] Valneva S.E.. (4/25/22). "Press Release: Valneva Provides Regulatory Update on its inactivated COVID-19 Vaccine Candidate". Saint-Herblain....
• [2] Valneva S.E.. (2/21/22). "Press Release: Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development". Saint-Herblain....
• [3] Valneva S.E.. (11/23/21). "Press Release: Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001". Saint-Herblain....
• [4] Valneva S.E.. (11/10/21). "Press Release: Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001". Saint-Herblain....
• [5] Valneva S.E.. (11/8/21). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint-Herblain....
• [6] Valneva S.E.. (10/29/21). "Press Release: Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares". Saint-Herblain....
• [7] Valneva S.E.. (10/26/21). "Press Release: Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares". Saint-Herblain....
• [8] Valneva S.E.. (10/18/21). "Press Release: Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001". Saint-Herblain....
• [9] Valneva S.E.. (9/13/21). "Press Release: Valneva Receives Notice of Termination of COVID-19 Vaccine Supply Agreement by UK Government". Saint-Herblain....
• [10] Valneva S.E.. (9/3/21). "Press Release: Valneva – U.S. DoD Exercises First Year Option on Ixiaro Supply Contract". Saint-Herblain....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2022. Made in Germany.